(Q46110704)

19 December 2017

title

A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer (English)

1 reference

19 December 2017

1 reference

Peter A Argenta

1

1 reference

19 December 2017

Sajeena G Thomas

2

1 reference

19 December 2017

Patricia L Judson

3

1 reference

19 December 2017

Levi S Downs

4

1 reference

19 December 2017

Melissa A Geller

5

1 reference

19 December 2017

Linda F Carson

6

1 reference

19 December 2017

Amy L Jonson

7

1 reference

19 December 2017

Rahel Ghebre

8

1 reference

19 December 2017

language of work or name

English

0 references

publication date

23 February 2009

1 reference

19 December 2017

published in

Gynecologic Oncology

1 reference

19 December 2017

volume

113

1 reference

19 December 2017

issue

2

1 reference

19 December 2017

page(s)

205-209

1 reference

19 December 2017

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Hormone replacement therapy and ovarian cancer risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

CA125 response: can it replace the traditional response criteria in ovarian cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Intracrinology of estrogens and androgens in breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Estrone sulfatase activity in patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.012

10.1016/J.YGYNO.2009.01.012

7 January 2021

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017